MDP 301
Status:Completed
Phase:III
Principal Investigator(s):Sheena McCormack
Objective:To determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels in preventing vaginally acquired HIV infection
Prevention Option(s):Microbicides
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
Description0.5% gel
Mode of DeliveryGel
ARMsExperimental
Official Code:
NCT00262106
Trial Sponsors:
Endo Pharmaceuticals
Start Date
End Date
October 31, 2005
September 30, 2009
Enrollment:9,404
Age range:
16 Years ↔
any
Population:Cisgender Women
MDP 301
Status:Completed
Phase:III
Principal Investigator(s):Sheena McCormack, MBBS, MSc, FRCP
Objective:To determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection.
Last updated May 16, 2021
Prevention Option(s):Microbicides
Study Design:
Arms and Assigned Interventions
Description
Mode of DeliveryGel
ARMs
Official Code:
NCT00262106
Trial Sponsors:
Endo Pharmaceuticals (ISRCTN64716212)
Start Date
End Date
October 1, 2005
September 30, 2009
Enrollment:9,404
Age range:
16 Years ↔
any
Population: